Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibody Structure and Classes01:25

Antibody Structure and Classes

8.4K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
8.4K
Drug Classes and Categories01:25

Drug Classes and Categories

3.1K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
3.1K
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

1.7K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
1.7K
Conjugated Proteins02:50

Conjugated Proteins

27.5K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
27.5K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.9K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.9K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2.

Nature cancer·2026
Same author

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Blood advances·2026
Same author

Organobodies: a robust and size-controllable system for generating scalable hiPSC-derived liver organoids for drug toxicity screening.

Biofabrication·2026
Same author

Integrated high-throughput miRNomics and lipidomics in mice with altered lipoprotein metabolism.

Atherosclerosis·2026
Same author

Immunosuppressive macrophages determine the effect of cellular senescence on tumor progression.

Science advances·2026
Same author

Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumonia.

Antimicrobial agents and chemotherapy·2025

Related Experiment Video

Updated: Jan 23, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.0K

MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.

Giuseppe Merlino1, Alessio Fiascarelli2, Mario Bigioni2

  • 1Department of Experimental and Translational Oncology, Menarini Ricerche SpA, Pomezia, Rome, Italy. gmerlino@menarini-ricerche.it.

Molecular Cancer Therapeutics
|June 23, 2019
PubMed
Summary

A novel antibody-drug conjugate, MEN1309/OBT076, targets CD205, showing potent activity against pancreatic, bladder, and triple-negative breast cancers (TNBC). This CD205-targeting therapy demonstrates significant anti-tumor effects in preclinical models, supporting its clinical development.

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.2K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.8K

Related Experiment Videos

Last Updated: Jan 23, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.0K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.2K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.8K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • CD205, a C-type lectin receptor, is highly expressed in various solid tumors, including pancreatic, bladder, and triple-negative breast cancer (TNBC).
  • Rapid internalization of CD205 upon binding suggests its potential as a target for drug delivery.

Purpose of the Study:

  • To evaluate the preclinical efficacy and characteristics of MEN1309/OBT076, a novel antibody-drug conjugate (ADC) targeting CD205.
  • To assess the anti-tumor activity of MEN1309/OBT076 in various solid malignancy models.

Main Methods:

  • Mass spectrometry and immunohistochemistry (IHC) were used to confirm CD205 expression in cancer tissues.
  • In vitro characterization included target binding, mechanism of action, and cytotoxicity assays.
  • In vivo studies utilized xenograft models derived from cell lines and patients.
  • Pharmacokinetic and pharmacodynamic analyses were performed in tumor-bearing mice.

Main Results:

  • MEN1309/OBT076 demonstrated potent and selective cytotoxic effects against CD205-expressing cancer cell lines.
  • Significant anti-tumor activity, including durable responses and complete regressions, was observed in TNBC, pancreatic, and bladder cancer xenograft models.
  • The ADC's serum levels correlated with its anti-tumor efficacy.

Conclusions:

  • MEN1309/OBT076 is a novel, selective ADC with potent activity against CD205-positive solid tumors.
  • Preclinical data support the ongoing clinical development of MEN1309/OBT076 in the SHUTTLE trial.